|
Leukopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Leucopenia occurred more often in the CYC group compared to the TwHF group (P = 0.034).
|
31713733 |
2020 |
|
Granulomatosis with polyangiitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Although the use of glucocorticoids with CYC is the most common drug combination, no differences in the outcome of the pituitary function and GPA disease course are seen with other immunosuppressants.
|
31446541 |
2020 |
|
Thrombocytopenia
|
0.650 |
GeneticVariation
|
phenotype |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
|
Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Patients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included.
|
31233287 |
2019 |
|
Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
A retrospective cohort of SSc subjects with ILD, disease duration below seven years and no exposure to CYC or MMF prior to the baseline visit was constructed from the Canadian Scleroderma Research Group registry.
|
31535689 |
2019 |
|
Systemic Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Patients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included.
|
31233287 |
2019 |
|
Systemic Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
A retrospective cohort of SSc subjects with ILD, disease duration below seven years and no exposure to CYC or MMF prior to the baseline visit was constructed from the Canadian Scleroderma Research Group registry.
|
31535689 |
2019 |
|
Lung Diseases, Interstitial
|
0.030 |
Biomarker
|
group |
BEFREE |
In both treatment arms (n = 71 for CYC, n = 62 for MMF), a higher baseline KL-6 level predicted progression of ILD based on the course of FVC (P = 0.024 for CYC; P = 0.005 for MMF) and DLco (P < 0.001 for CYC; P = 0.004 for MMF) over 1 year.
|
31233287 |
2019 |
|
Lung Diseases, Interstitial
|
0.030 |
Biomarker
|
group |
BEFREE |
Our aim was to determine whether use of CYC or MMF was associated with an improved ILD course in patients with normal or mildly impaired lung function.
|
31535689 |
2019 |
|
Malignant Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Patients were called in and a standard form was used for collecting demographic characteristics, indication for CYC, its cumulative dose and short term adverse events, defined as those causing discontinuation of CYC, hospitalization and/or death, long term adverse events, including infertility and malignancy, and outcome.
|
31840168 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Patients were called in and a standard form was used for collecting demographic characteristics, indication for CYC, its cumulative dose and short term adverse events, defined as those causing discontinuation of CYC, hospitalization and/or death, long term adverse events, including infertility and malignancy, and outcome.
|
31840168 |
2019 |
|
Angina, Unstable
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eighty-four consecutive type 2 diabetic patients with unstable angina (UA) were included from January 2018 to June 2018 to calculate calcification scores using computerized tomographic angiography (CTA), and the patients were divided into 2 groups: high calcification score group (HCS group) and low calcification score group (LCS group).
|
31452690 |
2019 |
|
Behcet Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYC remains an important treatment option for Behçet's syndrome (BS) patients with life-threatening manifestations.
|
31840168 |
2019 |
|
Bloom Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated short and long term adverse events associated with CYC use in BS patients.
|
31840168 |
2019 |
|
Chediak-Higashi Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We used two human CHS cell lines SW1353 and HCS-2/8 to analyze the expression profiles of ADAM8 in CHS cells compared with the normal chondrocytes.
|
31305294 |
2019 |
|
Lupus Nephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Treatment with a combined immunosuppressive agent is superior to routine CYC only therapy in lupus nephritis.
|
30488367 |
2019 |
|
Retinitis Pigmentosa
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: CYCS: cytochrome c; bRHO<sup>P23H</sup>: bovine RHO<sup>P23H</sup>; Cas9: CRISPR associated protein 9; dpf: days post-fertilization; eGFP: enhanced green fluorescent protein; GNAT1: guanine nucleotide-binding protein G(t) subunit alpha-1 aka rod alpha-transducin; HSPA1A/hsp70: heat shock protein of 70 kilodaltons; LAMP1: lysosomal-associated membrane protein 1; LC3: microtubule-associated protein 1A/1B light chain 3; mRFP: monomeric red fluorescent protein; RHO: rhodopsin; RP: retinitis pigmentosa; RPE65: retinal pigment epithelium-specific 65 kDa protein: sfGFP: superfolding GFP; sgRNA: single guide RNA; WGA: wheat germ agglutinin; <i>RHO<sub>p</sub></i>: the <i>Xenopus laevis RHO.2.L</i> promoter.
|
30975014 |
2019 |
|
Vasculitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, adverse events may occur with CYC and this has led to increased use of biologic agents in other vasculitides.
|
31840168 |
2019 |
|
Frontotemporal dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> 4HPR: 4-hydroxy(phenyl)retinamide; AKT: AKT1 serine/threonine kinase 1; ALS: amyotrophic lateral sclerosis; ATG: autophagy related; AVs: autophagic vesicle; C9orf72: chromosome 9 open reading frame 72; CASP3: caspase 3; CHAT: choline O-acetyltransferase; CYCS: cytochrome c, somatic; DIV: day in vitro; FTD: frontotemporal dementia; FUS: FUS RNA binding protein; GFP: green fluorescent protein; hiPSCs: human induced pluripotent stem cells; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MNs: motoneurons; mRFP: monomeric red fluorescent protein; MTOR: mechanistic target of rapamycin kinase; NFE2L2/NRF2: nuclear factor, erythroid 2 like 2; RARA: retinoic acid receptor alpha; SLC18A3/VACHT: solute carrier family 18 (vesicular acetylcholine transporter), member 3; SQSTM1/p62: sequestosome 1; TBK1: TANK binding kinase 1; TEM: transmission electron microscopy.
|
30939964 |
2019 |
|
Diffuse Scleroderma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We concluded that i.v.CYC pulse therapy should be considered as an effective treatment option for skin thickening in dcSSc patients, because 43% of this group of patients were found to have a clinically relevant response.
|
31628802 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Then, by silencing or overexpressing ADAM8, the effects on cell migration and invasion in SW1353 and HCS-2/8, and the downstream signal transduction pathways were evaluated.
|
31305294 |
2019 |
|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall outcomes were comparable to those of two matched cohorts (n = 172) from previous European Vasculitis Society (EUVAS) trials, but with lower total exposure to CYC and GCs (P < 0.001) and reduced rates of severe infections (P = 0.02) compared with the RITUXVAS (rituximab versus cyclophosphamide in AAV) trial.
|
30239910 |
2019 |
|
Thrombocytopenia 4
|
0.710 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
A novel CYCS mutation in the α-helix of the CYCS C-terminal domain causes non-syndromic thrombocytopenia.
|
30051457 |
2018 |
|
Chondrosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effect of long-term exposure to 5% low oxygen atmosphere on human chondrosarcoma HCS-2/8 cells.
|
28865129 |
2018 |
|
Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
RTX is a safe and effective alternative to CYC in the primary therapy of skin and lung manifestations of scleroderma.
|
30053212 |
2018 |